Caplin Point Laboratories Limited (BOM:524742)
2,623.15
+158.50 (6.43%)
At close: Jul 27, 2026
Caplin Point Laboratories Market Cap
Caplin Point Laboratories has a market cap or net worth of 199.39 billion as of July 27, 2026. Its market cap has increased by 28.77% in one year.
Market Cap
199.39B
Enterprise Value
190.56B
Revenue
21.87B
Ranking
n/a
PE Ratio
31.19
Stock Price
2,623.15
ChartMarket Cap Chart
Since February 26, 2002, Caplin Point Laboratories's market cap has increased from 5.60M to 199.39B, an increase of 3,561,073.07%. That is a compound annual growth rate of 53.57%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 27, 2026 | 199.39B | 42.47% |
| Dec 31, 2025 | 139.95B | -26.39% |
| Dec 31, 2024 | 190.12B | 84.60% |
| Dec 29, 2023 | 102.99B | 90.47% |
| Dec 30, 2022 | 54.07B | -16.82% |
| Dec 31, 2021 | 65.01B | 69.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| GlaxoSmithKline Pharmaceuticals | 425.76B |
| J. B. Chemicals & Pharmaceuticals | 387.31B |
| Rubicon Research | 250.45B |
| Granules India | 206.58B |
| AstraZeneca Pharma India | 200.00B |
| Jubilant Pharmova | 152.38B |
| CORONA Remedies | 129.23B |
| Procter & Gamble Health | 111.61B |